Therefore, we studied the effects of BRAFV600E, MET activation, and EGFRT790M, alone or in combination, on growth and therapeutic response in human EGFR-mutant lung adenocarcinoma cellular models. This evidence concerns the gene MET and lung adenocarcinoma.